P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
<p>Abstract</p> <p>Background</p> <p>We investigated the immunohistochemical expression of p53, MAPK, topoisomerase II alpha (topoII alpha) and Ki67 in ovarian serous carcinomas (OSCs) along with mutational analysis for KRAS and BRAF.</p> <p>Methods</p>...
Saved in:
Main Authors: | Sundov Dinka (Author), Caric Ana (Author), Mrklic Ivana (Author), Gugic Dijana (Author), Capkun Vesna (Author), Hofman Irena Drmic (Author), Mise Branka Petric (Author), Tomic Snjezana (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2013-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
by: Yan Xu, et al.
Published: (2017) -
KRAS and BRAF Mutation in Borderline Epithelial Type Ovarian Tumor
by: Dodi Suardi
Published: (2013) -
Role of topoisomerase II α and Ki -67 biomarkers in pituitary tumors
by: Chhanda Das, et al.
Published: (2023) -
KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020) -
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012)